Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 2
1990 1
1991 1
1993 2
1994 2
1995 1
1996 1
1997 4
1998 5
1999 7
2000 6
2001 8
2002 13
2003 15
2004 24
2005 21
2006 26
2007 20
2008 25
2009 37
2010 43
2011 27
2012 27
2013 29
2014 30
2015 21
2016 18
2017 14
2018 8
2019 9
2020 5
2021 13
2022 13
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

414 results

Results by year

Filters applied: . Clear all
Page 1
Cognitive enhancement effects of stimulants: a randomized controlled trial testing methylphenidate, modafinil, and caffeine.
Repantis D, Bovy L, Ohla K, Kühn S, Dresler M. Repantis D, et al. Psychopharmacology (Berl). 2021 Feb;238(2):441-451. doi: 10.1007/s00213-020-05691-w. Epub 2020 Nov 17. Psychopharmacology (Berl). 2021. PMID: 33201262 Free PMC article. Clinical Trial.
Widely available stimulants such as caffeine, but also prescription substances such as methylphenidate and modafinil, are being used by healthy individuals to enhance cognitive performance. ...METHODS: We conducted a pilot study with three arms in which male participants r …
Widely available stimulants such as caffeine, but also prescription substances such as methylphenidate and modafinil, are being used …
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.
Nourbakhsh B, Revirajan N, Morris B, Cordano C, Creasman J, Manguinao M, Krysko K, Rutatangwa A, Auvray C, Aljarallah S, Jin C, Mowry E, McCulloch C, Waubant E. Nourbakhsh B, et al. Lancet Neurol. 2021 Jan;20(1):38-48. doi: 10.1016/S1474-4422(20)30354-9. Epub 2020 Nov 23. Lancet Neurol. 2021. PMID: 33242419 Free PMC article. Clinical Trial.
FINDINGS: Between Oct 4, 2017, and Feb 27, 2019, of 169 patients screened, 141 patients were enrolled and randomly assigned to one of four medication administration sequences: 35 (25%) patients to the amantadine, placebo, modafinil, and methylphenidate sequence; 34 (24%) p …
FINDINGS: Between Oct 4, 2017, and Feb 27, 2019, of 169 patients screened, 141 patients were enrolled and randomly assigned to one of four m …
Cognitive enhancement: Effects of methylphenidate, modafinil, and caffeine on latent memory and resting state functional connectivity in healthy adults.
Becker M, Repantis D, Dresler M, Kühn S. Becker M, et al. Hum Brain Mapp. 2022 Oct 1;43(14):4225-4238. doi: 10.1002/hbm.25949. Epub 2022 Jun 7. Hum Brain Mapp. 2022. PMID: 35670369 Free PMC article. Clinical Trial.
Stimulants like methylphenidate, modafinil, and caffeine have repeatedly shown to enhance cognitive processes such as attention and memory. ...Here, we utilized behavioral and resting-state fMRI data from a double-blind randomized placebocontrolled study of methylphenidate …
Stimulants like methylphenidate, modafinil, and caffeine have repeatedly shown to enhance cognitive processes such as attention and m …
Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial.
Dauvilliers Y, Bassetti C, Lammers GJ, Arnulf I, Mayer G, Rodenbeck A, Lehert P, Ding CL, Lecomte JM, Schwartz JC; HARMONY I study group. Dauvilliers Y, et al. Lancet Neurol. 2013 Nov;12(11):1068-75. doi: 10.1016/S1474-4422(13)70225-4. Epub 2013 Oct 7. Lancet Neurol. 2013. PMID: 24107292 Clinical Trial.
Using a computer-generated randomisation sequence, we randomly allocated patients to receive pitolisant, modafinil, or placebo (1:1:1). Treatment lasted 8 weeks: 3 weeks of flexible dosing according to investigator's judgment (10 mg, 20 mg, or 40 mg a day of pitolisant; 10 …
Using a computer-generated randomisation sequence, we randomly allocated patients to receive pitolisant, modafinil, or placebo (1:1:1 …
Efficacy of Treatment With Armodafinil for Cancer-Related Fatigue in Patients With High-grade Glioma: A Phase 3 Randomized Clinical Trial.
Porter AB, Liu H, Kohli S, Cerhan JL, Sloan J, McMurray RP, Le-Rademacher J, Loprinzi CL, Villano JL, Kizilbash SH, Mehta MP, Jaeckle KA, Brown PD. Porter AB, et al. JAMA Oncol. 2022 Feb 1;8(2):259-267. doi: 10.1001/jamaoncol.2021.5948. JAMA Oncol. 2022. PMID: 34882169 Free PMC article. Clinical Trial.
OBJECTIVE: To determine whether armodafinil reduces fatigue in patients with HGG and moderate-to-severe fatigue. ...The study was conducted from June 2013 to December 15, 2019. INTERVENTIONS: Patients were randomized to 150 mg of armodafinil, 250 mg of armodafini
OBJECTIVE: To determine whether armodafinil reduces fatigue in patients with HGG and moderate-to-severe fatigue. ...The study was con …
Does Armodafinil Improve Driving Task Performance and Weight Loss in Sleep Apnea? A Randomized Trial.
Chapman JL, Cayanan EA, Hoyos CM, Serinel Y, Comas M, Yee BJ, Wong KKH, Grunstein RR, Marshall NS. Chapman JL, et al. Am J Respir Crit Care Med. 2018 Oct 1;198(7):941-950. doi: 10.1164/rccm.201712-2439OC. Am J Respir Crit Care Med. 2018. PMID: 29775087 Clinical Trial.
Patients on armodafinil lost 2.4 kg more fat than those on placebo at 6 months (95% confidence interval, 0.9-4.0; P = 0.002). Other secondary outcomes were not significantly improved. CONCLUSIONS: Armodafinil did not improve driving task performance at the primary e …
Patients on armodafinil lost 2.4 kg more fat than those on placebo at 6 months (95% confidence interval, 0.9-4.0; P = 0.002). Other s …
Armodafinil to reduce the sleepiness related side-effects of sleep restriction therapy being used to treat insomnia disorder: An open label clinical trial pilot study compared with historical controls.
Judge DJ, Miller CB, Bartlett DJ, Jomaa I, Wong KKW, Saini B, Semsarian CR, Espie CA, Kyle SD, Grunstein RR, Yee BJ, Marshall NS. Judge DJ, et al. J Sleep Res. 2023 Feb;32(1):e13699. doi: 10.1111/jsr.13699. Epub 2022 Aug 24. J Sleep Res. 2023. PMID: 36003019 Free PMC article. Clinical Trial.
This pilot trial aims to explore the potential benefit of armodafinil, a wakefulness promoter. Patients were treated with SRT with open label adjunctive armodafinil (150 mg/day). ...Sleep restriction therapy plus armodafinil treatment was associated with freq …
This pilot trial aims to explore the potential benefit of armodafinil, a wakefulness promoter. Patients were treated with SRT with op …
Efficacy and tolerability of armodafinil: effect on clinical condition late in the shift and overall functioning of patients with excessive sleepiness associated with shift work disorder.
Erman MK, Seiden DJ, Yang R, Dammerman R. Erman MK, et al. J Occup Environ Med. 2011 Dec;53(12):1460-5. doi: 10.1097/JOM.0b013e318237a17e. J Occup Environ Med. 2011. PMID: 22104981 Clinical Trial.
OBJECTIVE: This study examined the effect of armodafinil on late-in-shift clinical condition, wakefulness, and overall functioning of patients with shift work disorder. ...Armodafinil was generally well tolerated. CONCLUSIONS: Armodafinil improved clinical co …
OBJECTIVE: This study examined the effect of armodafinil on late-in-shift clinical condition, wakefulness, and overall functioning of …
Effects of cognitive behavioral therapy for insomnia and armodafinil on quality of life in cancer survivors: a randomized placebo-controlled trial.
Peoples AR, Garland SN, Perlis ML, Savard J, Heckler CE, Kamen CS, Ryan JL, Mustian KM, Janelsins MC, Peppone LJ, Morrow GR, Roscoe JA. Peoples AR, et al. J Cancer Surviv. 2017 Jun;11(3):401-409. doi: 10.1007/s11764-017-0597-0. Epub 2017 Jan 19. J Cancer Surviv. 2017. PMID: 28105576 Free PMC article. Clinical Trial.
The present analysis examines the effects of CBT-I, with and without armodafinil, on QOL both directly and indirectly through improvements of insomnia. ...RESULTS: Mean change in QOL from pre- to post-intervention for CBT-I + placebo, CBT-I + armodafinil, armodaf
The present analysis examines the effects of CBT-I, with and without armodafinil, on QOL both directly and indirectly through improve …
Modafinil and armodafinil treatment for fatigue for HIV-positive patients with and without chronic hepatitis C.
Rabkin JG, McElhiney MC, Rabkin R. Rabkin JG, et al. Int J STD AIDS. 2011 Feb;22(2):95-101. doi: 10.1258/ijsa.2010.010326. Int J STD AIDS. 2011. PMID: 21427431 Clinical Trial.
Fatigue is prevalent among patients with hepatitis C virus (HCV) and with HIV/AIDS but there are no established fatigue treatments for either condition or their combination. We analysed data from three trials of modafinil or armodafinil for HIV-positive patients wit …
Fatigue is prevalent among patients with hepatitis C virus (HCV) and with HIV/AIDS but there are no established fatigue treatments for eithe …
414 results